Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Aditya Birla Capital Q4 FY26 Results | Wockhardt Q4 FY26 Results | Top Buzzing Stocks Today - Equitymaster
Aditya Birla Capital Q4 FY26 Results | Wockhardt Q4 FY26 Results | Top Buzzing Stocks TodayEquitymaster
Kumar Birla back as Vodafone Idea’s non-exec Chair amid turnaround attempt
Kumar Mangalam Birla has returned as non-executive chairman of Vodafone Idea (Vi) to lead its turnaround. The company, bolstered by government relief and a $5 billion capital expenditure, aims to secure debt funding and achieve significant revenue and EBITDA growth. Birla expressed confidence in Vi's role in India's digital future.
Q4 Results LIVE Updates: DMart shares down 4%, ideaForge Technologies up 16%; Ambuja report today
Q4 Results LIVE Updates: Amubja Cements, Manappuram Finance, Godrej Properties, Aditya Birla Capital, Tata Technologies, KEI Industries, Jindal Stainless, BHEL, Aarti Industries, Sobha, Quess Corp, Tata Chemicals, Wockhardt, are among the companies reporting their earnings today. Also watch for earnings reactions from Avenue Supermarts, Kotak Mahindra Bank, CDSL, NSDL, Zen Technologies, Mazagon Dock and others. Watch this space for all the LIVE earnings reactions.
RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-September
RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.
‘Debt Averse, Not Risk Averse’: Dilip Shanghvi on Sun Pharma’s shift to net debt for Organon deal
Addressing concerns around Organon’s muted revenue growth in recent years, Managing Director Kirti Ganorkar said there are multiple levers to drive growth across its businesses.
Sun Pharma a trading play on dips, banks may face difficult June quarter: Dharmesh Kant
Dharmesh Kant, Head of Research at Chola Securities, said Sun Pharma’s all-cash acquisition of Organon could improve return ratios and support valuations, but may bring overall revenue growth down to single digits. He sees a trading opportunity in Sun Pharma on price dips. On banking, he said Q1 could be difficult as provisioning picks up, which may weigh on profitability even as asset quality and margins remain stable. Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own, not of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
Muthoot Finance seeks shareholder nod for entry into insurance distribution biz
Muthoot Finance is gearing up for a pivotal growth phase as it seeks shareholder approval to venture into the insurance distribution arena. This bold step encompasses a wide range of offerings, including life, general, and health insurance products, marking the company's ambition to become a comprehensive corporate agent in India's insurance landscape.
Stock to buy: Jefferies lists 10 reasons to buy its top CRDMO pick Sai Life Sciences
Jefferies has initiated coverage on Sai Life Sciences with a 'Buy' rating and a Rs 1,300 target price, citing its integrated 'follow-the-molecule' model and strong growth outlook. The brokerage highlighted the company's healthy pipeline, global presence, and clean balance sheet as key investment drivers, projecting significant upside potential.
Nomura’s Saion Mukherjee picks Dr Reddy’s as top pharma bet amid semaglutide opportunity
Saion Mukherjee, Managing Director & Head of Equity Research at Nomura says Indian pharmaceutical companies are preparing to tap the opportunity as semaglutide goes off patent. While several large firms such as Sun Pharma, Lupin and Zydus could benefit from the growing diabetes and obesity drug market, Mukherjee highlighted Dr Reddy’s as his top pick in the sector. He said the opportunity will play out across domestic and global markets, with semaglutide likely to become an important growth driver for Indian pharma companies in the coming years.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 9 March 2026
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Aditya Birla Sun Life Amc, Aster DM Healthcare, CG Power and Industrial Solutions, Astral, and Krishna Institute Of Medical Sciencs.
Sai Life hits record high in weak market; rebounds 5% from day's low
Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.
Elara Securities bets on pharma revival; picks Zydus Life, Sun Pharma, Aurobindo Pharma
Bino Pathiparampil, Head of Research at Elara Securities believes the broader pharma space is entering a more favourable phase as pricing concerns and regulatory worries ease while currency movements provide an additional boost.